Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an update.
Ondine Biomedical Inc. announced the appointment of Strand Hanson Limited as its new Nominated and Financial Adviser, while RBC Capital Markets will now serve as the sole broker. This strategic move is expected to reinforce Ondine’s financial advisory framework and support its ongoing efforts to expand the presence of its photodisinfection technology in the market. The appointment is poised to enhance the company’s industry positioning and potentially impact its operations positively.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, with applications for nasal disinfection, chronic sinusitis, ventilator-associated pneumonia, and more. Ondine’s nasal photodisinfection system is approved in multiple countries, including Canada and Europe, and is undergoing clinical trials in the US.
YTD Price Performance: 42.86%
Average Trading Volume: 520,482
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £50.5M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.
